300452.SZ
山河药辅
SZSE · Healthcare · C 制造业 · CN
CNY 12.58
−1.49%Year over year
Reported trailing growth
- Revenue
- +7.1%
- EBITDA
- —
- EBIT
- +43.9%
- EPS
- +51.5%
- Free cash flow
- +87.6%
- Operating cash flow
- +74.3%
Forward estimates
Based on analyst estimates
- Revenue
- +9.7%
- EBITDA
- +5.4%
- EPS
- -4.5%
Three-year CAGR
- Revenue
- +10.2%
- EBITDA
- +13.7%
- EBIT
- +13.5%
- Net income
- +10.5%
- EPS
- +10.2%
- Free cash flow
- +32.2%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026